• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Vaccine . Pneumococcal and influenza vaccination coverage and impact on COVID-19 infection severity in patients with inflammatory rheumatic diseases

tetano

Editor, Senior Moderator
Vaccine


. 2025 Jul 1:61:127439.
doi: 10.1016/j.vaccine.2025.127439. Online ahead of print. Pneumococcal and influenza vaccination coverage and impact on COVID-19 infection severity in patients with inflammatory rheumatic diseases: A French National Healthcare Database analysis

Maxime Auroux[SUP] 1 [/SUP], Thibaut Fabacher[SUP] 2 [/SUP], Erik Sauleau[SUP] 2 [/SUP], Laurent Arnaud[SUP] 3 [/SUP], Fabienne Coury[SUP] 4 [/SUP]



Affiliations
Abstract

Introduction: It has been suggested that vaccinations could induce a trained immunity able to decrease COVID-19 severity. Our primary aim was to evaluate the COVID-19 severity among patients with inflammatory rheumatic diseases (IRD) vaccinated against pneumococcus and influenza compared to those not vaccinated. A secondary objective was also to determine vaccination coverage within real-life population of IRD patients in France.
Methods: We conducted a longitudinal study within the French administrative and medical data base (SNDS). We have identified patients with one following of these IRD: rheumatoid arthritis (RA), spondyloarthritis (SpA) and psoriatic arthritis (PsA). COVID-19 infected patients were identified using CIM-10 code and vaccination status was extracted from the database.
Results: 406,156 patients were identified, with 64.6 % women and a mean age of 62.2 years. Pneumococcal and influenza vaccination rate in this population were respectively 37.8 % and 40.5 %. We recorded 0.9 % COVID-19 hospitalizations (n = 3574), 0.24 % severe infections (n = 980), and 0.17 % deaths (n = 697). Multivariate analysis demonstrated pneumococcal vaccination's association with decreased risks of hospitalization (OR 0.84 IR95 %[0.78-0.91] p < 0.0001), severe COVID-19 forms (OR 0.83 IR95 %[0.72-0.96] p < 0.05), and death (OR 0.82 IR95 %[0.70-0.97] p < 0.05), while influenza vaccination associated with increased risks of these outcomes (OR 1.47 IR95 %[1.36-1.58] p < 0.0001, OR 1.54 IR95 %[1.33-1.78] p < 0.0001, OR 1.62 IR95 %[1.36-1.93] p < 0.0001, respectively).
Conclusions: Pneumococcal vaccination was associated with a reduced hospitalization rate, and occurrence of severe forms of COVID-19, including death, among infected patients. These findings suggest the possible involvement of vaccine-induced trained immunity in shaping the immune response to other infections especially COVID-19.

Keywords: COVID-19; Inflammatory rheumatic disease; Influenza vaccination; Pneumococcal vaccination; Trained immunity.

 
Back
Top Bottom